Estrella Immunopharma Total Debt vs. Cash Flow From Operations
| ESLAW Stock | 0.09 0 1.10% |
For Estrella Immunopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Estrella Immunopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Estrella Immunopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Estrella Immunopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Estrella Immunopharma over time as well as its relative position and ranking within its peers.
Estrella |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (1.75) |
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Estrella Immunopharma Cash Flow From Operations vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Estrella Immunopharma's current stock value. Our valuation model uses many indicators to compare Estrella Immunopharma value to that of its competitors to determine the firm's financial worth. Estrella Immunopharma is rated below average in total debt category among its peers. It is rated # 3 in cash flow from operations category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Estrella Immunopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Estrella Total Debt vs. Competition
Estrella Immunopharma is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 388.21 Million. Estrella Immunopharma adds roughly 180,701 in total debt claiming only tiny portion of equities under Health Care industry.
Estrella Cash Flow From Operations vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Estrella Immunopharma |
| = | 180.7 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Estrella Immunopharma |
| = | (16.07 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Estrella Cash Flow From Operations Comparison
Estrella Immunopharma is currently under evaluation in cash flow from operations category among its peers.
Estrella Immunopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Estrella Immunopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Estrella Immunopharma will eventually generate negative long term returns. The profitability progress is the general direction of Estrella Immunopharma's change in net profit over the period of time. It can combine multiple indicators of Estrella Immunopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3.3 K | -3.5 K | |
| Operating Income | -7.3 M | -6.9 M | |
| Net Loss | -7.3 M | -6.9 M | |
| Income Before Tax | -7.3 M | -6.9 M | |
| Net Loss | -7.3 M | -6.9 M | |
| Income Tax Expense | 1.6 K | 1.7 K | |
| Total Other Income Expense Net | 588.7 K | 836.7 K | |
| Net Loss | (0.21) | (0.17) | |
| Income Quality | 2.20 | 1.05 | |
| Net Income Per E B T | 1.00 | 1.09 |
Estrella Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Estrella Immunopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Estrella Immunopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Estrella Immunopharma's important profitability drivers and their relationship over time.
Use Estrella Immunopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Estrella Immunopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Estrella Immunopharma will appreciate offsetting losses from the drop in the long position's value.Estrella Immunopharma Pair Trading
Estrella Immunopharma Pair Trading Analysis
The ability to find closely correlated positions to Estrella Immunopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Estrella Immunopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Estrella Immunopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Estrella Immunopharma to buy it.
The correlation of Estrella Immunopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Estrella Immunopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Estrella Immunopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Estrella Immunopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Estrella Immunopharma position
In addition to having Estrella Immunopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.